3 reports

  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, FORECAST REVENUES BY COMPANY, 2015-2022
  • Company Analysis and Positioning

Only one JAK inhibitor, Xeljanz, is approved for the immunology market.

  • Autoimmune Disease
  • Immunology
  • Monoclonal Antibody
  • Therapy
  • GlaxoSmithKline plc

In the study, ## patients were randomized ##:##:## to receive placebo, baricitinib ## mg or baricitinib ## mg.

  • Clinical Trial
  • Immunology
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • GlaxoSmithKline plc

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## ## UCB SA ## ## ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Q

  • Autoimmune Disease
  • Clinical Trial
  • Immunology
  • Musculoskeletal Disorder
  • GlaxoSmithKline plc